

<b>Statement of Deficiencies</b>	<b>(X1) Provider/Supplier/CLIA Identification Number</b>  44D1011560	<b>(X3) Date Survey Completed</b>  09/21/2020
<b>Name of Provider or Supplier</b>  Katherine W Jones Md Plc	<b>Street Address, City, State</b>  40 West Caldwell Street Suite 100, Mount Juliet, TN	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

<b>(X4) ID Prefix Tag</b>	<b>Summary Statement of Deficiencies</b>
<b>D2016</b>	<p><b>SUCCESSFUL PARTICIPATION</b> CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: The laboratory failed to maintain satisfactory proficiency testing (PT) performance in two out of three testing events for the Red Blood Cell (RBC) analyte resulting in the 1st unsuccessful PT occurrence for the RBC analyte in 2020. (Refer to D2130)</p>
<b>D2130</b>	<p><b>HEMATOLOGY</b> CFR(s): 493.851(f)</p> <p>Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance.</p>

This STANDARD is not met as evidenced by:

Based on a review of the Centers for Medicare and Medicaid Services Casper report 155 (CMS 155) and American Proficiency Institute (API) evaluation reports, the laboratory failed to achieve satisfactory performance for Red Blood Cell (RBC) analyte in two out of three testing event resulting in the 1st unsuccessful PT performance in 2020. The findings include: 1. 1) Review of the CMS 155 revealed the following scores for the RBC analyte: 2019 Event three = 60% 2020 Event two = 60% 2. Review of the laboratory's API evaluation report revealed the RBC analyte with a score of 60% for the 3rd event 2019, and a score of 60% for the 2nd event in 2020.